Impact of the era of diabetes onset in a national care system on the prevalence of retinopathy and microalbuminuria in people living with type 1 diabetes 15 years post-diagnosis: A cross-sectional, real-world observational study. - 2025
Impact of the era of diabetes onset in a national care system on the prevalence of retinopathy and microalbuminuria in people living with type 1 diabetes 15 years post-diagnosis: A cross-sectional, real-world observational study.
Lavens, Astrid; De Block, Christophe; Oriot, Philippeet al.
2025 • In Diabetes, Obesity and Metabolism, 27 (11), p. 6499 - 6506
microvascular complications; real‐world data; type 1 diabetes; Glycated Hemoglobin; hemoglobin A1c protein, human; Humans; Female; Male; Adult; Prevalence; Cross-Sectional Studies; Young Adult; Age of Onset; Adolescent; Glycated Hemoglobin/metabolism; Glycated Hemoglobin/analysis; Child; Diabetes Mellitus, Type 1/complications; Diabetes Mellitus, Type 1/epidemiology; Diabetes Mellitus, Type 1/blood; Albuminuria/epidemiology; Albuminuria/etiology; Diabetic Retinopathy/epidemiology; Diabetic Retinopathy/etiology; Diabetic Retinopathy/prevention & control; Diabetic Nephropathies/epidemiology; Albuminuria; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Diabetic Retinopathy; Internal Medicine; Endocrinology, Diabetes and Metabolism; Endocrinology
Abstract :
[en] [en] AIMS: This study investigates the impact of the era of diabetes onset on the prevalence of diabetic retinopathy and albuminuria 15 years post-diagnosis in people living with type 1 diabetes (T1D) within a national healthcare system offering structured multidisciplinary endocrinology care.
MATERIALS AND METHODS: We analysed data of 2176 individuals diagnosed with T1D before age 30, comparing two cohorts based on diabetes onset period: group A (1985-1998) and group B (1998-2009). The prevalence of diabetic retinopathy and albuminuria was assessed using generalised estimating equations.
RESULTS: Glycaemic control (haemoglobin A1C: 8.3% vs. 8.1%, p < 0.0001) and low density lipoprotein cholesterol (2.6 mmol/L vs. 2.5 mmol/L, p < 0.001) were poorer in group A, whereas obesity prevalence was higher in group B (12.8% vs. 17.4%, p < 0.01). Group A used more antihypertensive therapy (14.9% vs. 11.5%, p < 0.01), while group B used more lipid-lowering therapy (9.2% vs. 15.9%, p < 0.0001). The prevalence of diabetic retinopathy 15 years post-diagnosis significantly declined from 36.3% in 2001 to 21.1% in 2022 (p < 0.0001). This decrease was particularly pronounced in individuals with diabetes onset after 11 years of age. The prevalence of albuminuria, adjusted for age and sex, decreased from 14.9% in 2001 to 7.3% in 2022 (p < 0.05).
CONCLUSIONS: Individuals diagnosed with T1D after 1998 had fewer microvascular complications 15 years post-diagnosis, especially less retinopathy in those with diabetes onset after age 11. This decline highlights the impact of improved care.
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
Lavens, Astrid ; Health Services Research, Sciensano, Brussels, Belgium
De Block, Christophe ; Department of Endocrinology, Diabetology and Metabolism, Antwerp University Hospital-UA, Antwerp, Belgium
Oriot, Philippe ; Department of Diabetology and Endocrinology, Mouscron Hospital Centre, Mouscron, Belgium
Philips, Jean-Christophe ; Université de Liège - ULiège > Département des sciences de la santé publique
Vandenbroucke, Michel; Department of Endocrinology, AZ Sint Maarten, Mechelen, Belgium
Crenier, Laurent ; Department of Endocrinology, HUB-Hôpital Erasme, Brussels, Belgium
Nobels, Frank ; Department of Endocrinology, AZORG, Aalst, Belgium
Mathieu, Chantal ; Clinical and Experimental Endocrinology, University Hospitals Leuven-KUL, Leuven, Belgium
Belgian Group of Experts IQED
Language :
English
Title :
Impact of the era of diabetes onset in a national care system on the prevalence of retinopathy and microalbuminuria in people living with type 1 diabetes 15 years post-diagnosis: A cross-sectional, real-world observational study.
INAMI - Institut National d'Assurance Maladie-Invalidité
Funding text :
This article is written on behalf of the Belgian Group of Experts IQED. The members of the IQED Group of Experts are L. Crenier, C. De Block, A. Lavens, C. Mathieu, F. Nobels, J. C. Philips, P. Oriot, M. Vandenbroucke and V. Vanelshocht. We would like to thank the staff of all Belgian specialised diabetes centres for the data collections. We also would like to thank our data manager N. Demeulemeester for the support during the data collections; and A. Laenen from the Leuven Biostatistics and Statistical Bioinformatics Centre for statistical advice.The IQED programme is funded by the Belgian National Institute for Health and Disability Insurance (NIHDI).
Harding JL, Pavkov ME, Magliano DJ, Shaw JE, Gregg EW. Global trends in diabetes complications: a review of current evidence. Diabetologia. 2019;62(1):3-16. doi:10.1007/s00125-018-4711-2
Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular outcomes in type 1 diabetes: the DCCT/EDIC study 30-year follow-up. Diabetes Care. 2016;39(5):686-693. doi:10.2337/dc15-1990
Gregg EW, Li Y, Wang J, et al. Changes in diabetes-related complications in the United States, 1990-2010. N Engl J Med. 2014;370(16):1514-1523. doi:10.1056/NEJMoa1310799
Carstensen B, Rønn PF, Jørgensen ME. Prevalence, incidence and mortality of type 1 and type 2 diabetes in Denmark 1996-2016. BMJ Open Diabetes Res Care. 2020;8(1):e001071. doi:10.1136/bmjdrc-2019-001071
Rawshani A, Rawshani A, Franzén S, et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med. 2017;376(15):1407-1418. doi:10.1056/NEJMoa1608664
McKnight JA, Wild SH, Lamb MJE, et al. Glycaemic control of type 1 diabetes in clinical practice early in the 21st century: an international comparison. Diabet Med. 2015;32(8):1036-1050. doi:10.1111/dme.12676
Prigge R, McKnight JA, Wild SH, et al. International comparison of glycaemic control in people with type 1 diabetes: an update and extension. Diabet Med. 2022;39(5):e14766. doi:10.1111/dme.14766
Lavens A, Nobels F, De Block C, et al. Effect of an integrated, multidisciplinary nationwide approach to type 1 diabetes care on metabolic outcomes: an observational real-world study. Diabetes Technol Ther. 2021;23(8):565-576. doi:10.1089/dia.2021.0003
Sciensano. Initiative for Quality Improvement and Epidemiology in Diabetes (IQED). Accessed February 21, 2024. https://www.sciensano.be/en/projects/initiative-quality-improvement-and-epidemiology-diabetes
Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499-502.
Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111-188. doi:10.1093/eurheartj/ehz455.
Erratum in: Eur Heart J. 2020;41(44):4255. doi:10.1093/eurheartj/ehz826
Madeira C, Lopes M, Laiginhas R, et al. Changing trends in the prevalence of diabetic retinopathy in type 1 diabetes mellitus from 1990 to 2018: a retrospective study in a Portuguese population. Diabetes Res Clin Pract. 2019;158:107891. doi:10.1016/j.diabres.2019.107891
Martínez-Ortega AJ, Muñoz-Gómez C, Gros-Herguido N, et al. Description of a cohort of type 1 diabetes patients: analysis of comorbidities, prevalence of complications and risk of hypoglycemia. J Clin Med. 2022;11(4):1039. doi:10.3390/jcm11041039
Surowiec P, Matejko B, Kopka M, et al. Low prevalence of diabetic retinopathy in patients with long-term type 1 diabetes and current good glycemic control – one-center retrospective assessment. Endocrine. 2022;75(2):427-436. doi:10.1007/s12020-021-02871-2
Zureik A, Julla JB, Erginay A, et al. Prevalence, severity stages, and risk factors of diabetic retinopathy in 1464 adult patients with type 1 diabetes. Graefes Arch Clin Exp Ophthalmol. 2021;259(12):3613-3623. doi:10.1007/s00417-021-05298-7
Hashemi H, Rezvan F, Pakzad R, et al. Global and regional prevalence of diabetic retinopathy; a comprehensive systematic review and meta-analysis. Semin Ophthalmol. 2022;37(3):291-306. doi:10.1080/08820538.2021.1962920
Pambianco G, Costacou T, Ellis D, Becker DJ, Klein R, Orchard TJ. The 30-year natural history of type 1 diabetes complications: the Pittsburgh epidemiology of diabetes complications study experience. Diabetes. 2006;55(5):1463-1469. doi:10.2337/db05-1423
Hovind P, Tarnow L, Rossing K, et al. Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes. Diabetes Care. 2003;26(4):1258-1264. doi:10.2337/diacare.26.4.1258
Nordwall M, Bojestig M, Arnqvist HJ, Ludvigsson J. Declining incidence of severe retinopathy and persisting decrease of nephropathy in an unselected population of type 1 diabetes—the Linköping diabetes complications study. Diabetologia. 2004;47(7):1266-1272. doi:10.1007/s00125-004-1431-6
Salardi S, Porta M, Maltoni G, et al. Decreasing prevalence of retinopathy in childhood-onset type 1 diabetes over the last decade: a comparison of two cohorts diagnosed 10 years apart. Diabetes Obes Metab. 2021;23(8):1950-1955. doi:10.1111/dom.14438
Bratina N, Auzanneau M, Birkebaek N, et al. Differences in retinopathy prevalence and associated risk factors across 11 countries in three continents: a cross-sectional study of 156,090 children and adolescents with type 1 diabetes. Pediatr Diabetes. 2022;23(8):1656-1664. doi:10.1111/pedi.13416
Lavens A, De Block C, Oriot P, et al. Metabolic health in people living with type 1 diabetes in Belgium: a repeated cross-sectional study. Diabetologia. 2024;13:2678-2690. doi:10.1007/s00125-024-06273-7
Rawshani A, Sattar N, Franzén S, et al. Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study. Lancet. 2018;392(10146):477-486. doi:10.1016/S0140-6736(18)31506-X
Edqvist J, Rawshani A, Adiels M, et al. BMI, mortality, and cardiovascular outcomes in type 1 diabetes: findings against an obesity paradox. Diabetes Care. 2019;42(7):1297-1304. doi:10.2337/dc18-1446
Sigfrids FJ, Groop PH, Harjutsalo V. Incidence rate patterns, cumulative incidence, and time trends for moderate and severe albuminuria in individuals diagnosed with type 1 diabetes aged 0–14 years: a population-based retrospective cohort study. Lancet Diabetes Endocrinol. 2022;10(7):489-498. doi:10.1016/S2213-8587(22)00099-7
Van der Schueren B, Ellis D, Faradji RN, Al-Ozairi E, Rosen J, Mathieu C. Obesity in people living with type 1 diabetes. Lancet Diabetes Endocrinol. 2021;9(11):776-785. doi:10.1016/S2213-8587(21)00246-1